Amylyx Pharmaceuticals Beats Q4 Loss Estimates, Projects Cash Runway Through 2028
AMLX has more than doubled off its 52-week low of $2.6.
Summary
Amylyx Pharmaceuticals reported better-than-expected Q4 2025 financial results, with its net loss, EPS, operating income, and pretax profit all beating analyst estimates. The company posted a Q4 EPS loss of -$0.30, outperforming the -$0.36 consensus. This positive earnings surprise is significant for a development-stage biotech firm. Crucially, Amylyx also provided an outlook stating its $317 million in cash and investments are expected to fund operations through 2028, significantly extending its cash runway and reducing near-term financing concerns. Investors will now closely monitor the upcoming topline data from the Phase 3 LUCIDITY trial in Q3 2026, which is a major catalyst for potential commercialization of avexitide in 2027, and the planned IND submission for AMX0318 in 2027.
At the time of this announcement, AMLX was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.60 to $17.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.